The Food and Drug Administration Modernization Act and the Food and Drug Administration: Metamorphosis or Makeover?

被引:0
|
作者
Christopher-Paul Milne
机构
[1] Tufts University,Tufts Center for the Study of Drug Development
来源
Drug information journal : DIJ / Drug Information Association | 2000年 / 34卷 / 3期
关键词
FDA Modernization Act; FDAMA; Food and Drug Administration; Rule making;
D O I
暂无
中图分类号
学科分类号
摘要
The Food and Drug Administration Modernization Act of 1997 (FDAMA) is the first legislation to bring about significant and widespread modifications to the regulatory environment for drugs and biologicals in more than 35 years. The expectations of what FDAMA is to accomplish are high. This article reviews the results from the first two years of implementation of the major FDAMA provisions for drugs and biologicals. First, however, the elements of the adversarial culture that brought about the impetus to modernize FDA are discussed. Next the article focuses on FDA’s more “modernized” approach to the process of governing, through the use of such mechanisms as governance by guidance, direct final rules, national videoconferences, and stakeholders meetings. In addition, the process for implementing FDAMA and what the products of that process have been, both the rules themselves and the outcomes for the regulated community, are discussed. Lastly, the article considers whether FDA is capable of change and what the real message of FDAMA is.
引用
收藏
页码:681 / 692
页数:11
相关论文
共 50 条
  • [41] Dorsal root ganglion stimulation approval by the Food and Drug Administration: advice on evolving the process
    Deer, Timothy R.
    Pope, Jason E.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1123 - 1125
  • [42] A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actions
    Lu, Christine Y.
    Hou, Laura
    Kolonoski, Joy
    Petrone, Andrew B.
    Zhang, Fang
    Corey, Catherine
    Huang, Ting-Ying
    Bradley, Marie C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (03) : 298 - 311
  • [43] Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021
    Kandemir, Esin Aysel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 191 - 207
  • [44] When are medical apps medical? Off-label use and the Food and Drug Administration
    Krieger, William H.
    DIGITAL HEALTH, 2016, 2
  • [45] Opportunities for Consumer Research from the Food and Drug Administration's Center for Tobacco Products
    Andrews, J. Craig
    Choiniere, Conrad J.
    Portnoy, David B.
    JOURNAL OF PUBLIC POLICY & MARKETING, 2015, 34 (01) : 119 - 130
  • [46] US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews
    McDonagh, Marian S.
    Peterson, Kim
    Balshem, Howard
    Helfand, Mark
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (10) : 1071 - 1081
  • [47] Academic perspectives on the United States food and drug administration's guidance for industry on diabetes mellitus
    Hennekens, Charles H.
    Hebert, Patricia R.
    Schneider, Wendy R.
    O'Brien, Peter
    DeMets, David
    Borer, Jeffrey S.
    CONTEMPORARY CLINICAL TRIALS, 2010, 31 (05) : 411 - 413
  • [48] What the Food and Drug Administration and the Pharmaceutical Industry Could Better Understand about Each Other
    Theresa L. Gerrard
    Drug information journal : DIJ / Drug Information Association, 2000, 34 : 305 - 309
  • [49] What the Food and Drug Administration and the pharmaceutical industry could better understand about each other
    Gerrard, TL
    DRUG INFORMATION JOURNAL, 2000, 34 (01): : 305 - 309
  • [50] Understanding Food and Drug Administration Regulatory Requirements for an Investigational Device Exemption for Sponsor-Investigators
    Holbein, M. E. Blair
    Berglund, Jelena Petrovic
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (07) : 987 - 994